FACULTAD DE FARMACIA
Facultad
MIGUEL ÁNGEL
CALLEJA HERNÁNDEZ
Investigador en el periodo 2016-2017
Publicaciones en las que colabora con MIGUEL ÁNGEL CALLEJA HERNÁNDEZ (71)
2024
-
Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study
Journal of Clinical Medicine, Vol. 13, Núm. 4
2023
-
Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review
Journal of Clinical Medicine, Vol. 12, Núm. 15
2021
-
Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis
Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47
-
Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives
Mutation Research - Reviews in Mutation Research, Vol. 788
-
Impact of a risk-sharing agreement in rheumatoid arthritis in Spain
Health Policy, Vol. 125, Núm. 3, pp. 335-340
-
Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis
Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726
-
Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis
Journal of Personalized Medicine, Vol. 11, Núm. 5
2020
-
Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis
Pathology Research and Practice, Vol. 216, Núm. 4
-
Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta
Mutation Research - Reviews in Mutation Research, Vol. 785
2019
-
Clinical pharmacy services: From cost-effectiveness analysis to a productivity indicators model
European Journal of Hospital Pharmacy
-
Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177
2018
-
Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer
Pathology Research and Practice, Vol. 214, Núm. 1, pp. 44-52
-
Pharmacogenetic biomarkers of response in Crohn's disease
Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 1-13
2017
-
ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis
Surgical Oncology, Vol. 26, Núm. 4, pp. 473-482
-
Adherence of psychopharmacological prescriptions to clinical practice guidelines in patients with eating behavior disorders
European Journal of Clinical Pharmacology, Vol. 73, Núm. 10, pp. 1305-1313
-
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58
-
Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer
Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444
-
Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer
Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285
-
Liquid chromatography tandem mass spectrometric determination of triterpenes in human fluids: Evaluation of markers of dietary intake of olive oil and metabolic disposition of oleanolic acid and maslinic acid in humans
Analytica Chimica Acta, Vol. 990, pp. 84-95
2016
-
ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients
Pharmacological Research, Vol. 108, pp. 111-118